Abstract. Inducible nitric oxide synthase (iNOS) is the key enzyme in NO synthesis and exhibits a high expression in numerous types of malignant tumors. Previous studies have demonstrated that iNOS promotes the production of tumor blood vessels by catalyzing the synthesis of additional NO.
Introduction
Cervical cancer is one of the most common malignant cancers in gynecology (1) (2) (3) . Recently, the incidence rate of the disease has increased and has demonstrated an increasing trend in younger females. However, the developmental process of the tumor is complex and involves numerous factors at various stages (4, 5) . Previous studies have demonstrated that angiogenesis was the foundation for tumor growth (6, 7) and that NO is one of the most secondary messengers and is capable of promoting the process (1) .
Vascular endothelial growth factor (VEGF) is considered to be one of the most significant of the 30 cytokines whose function it is to promote vascular production (8) . VEGF increases cancer cell growth by promoting the cleavage and proliferation of tumor cells by binding to the tyrosinase receptor (9) (10) (11) .
Inducible nitric oxide synthase (iNOS) is a key enzyme in NO synthesis and has a high expression in numerous types of malignant tumors. Previous studies have demonstrated that iNOS promotes the production of tumor blood vessels by catalyzing the synthesis of additional NO (9, 12) . Experimental evidence has suggested that iNOS may emerge as a VEGF enhancer, due to the fact that the VEGF level is capable of being induced by iNOS in endothelial cell migration and angiogenesis (13) . However, the correlation between iNOS and VEGF in cervical cancer remains unclear (11, 14) .
Materials and methods
Cell culture. Two human cervical carcinoma cell lines, Hela and SiHa, which exhibit relatively low metastatic capability, were obtained from the China Center for Type Culture Collection (Wuhan, China). Cells were all cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) in an atmosphere of 5% CO 2 and 95% air. SiHa and HeLa cells were plated in 6-well plates.
Quantitative polymerase chain reaction (qPCR).
Total RNA was extracted from 1x10 6 human SiHa and HeLa cells using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA). Aliquots (1 g) of RNA were reverse transcribed to cDNA and aliquots (4 µl) of cDNA were used as a template for qPCR using an ABI7900HT PCR system (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. The primers were as follows: For wa rd: 5'-TG GAGAGA A ACTGA AGA A ATCG -3' and reverse 5'-GTACCTGAATTTGTTGTTGAGC-3' for iNOS; forward: 5'-GCTGTGAAGCCAGACAGC-3' and reverse: 5'-GGCAAGTCACCCTGCTGA-3' for VEGF; and forward: 5'-CTCCATCCTGGCCTCGCTGT-3' and reverse: 5'-GCTGTCACCTTCACCGTTCC-3' for β-actin (ACTB). All experiments were performed in triplicate, with each reading taken three times. Average and standard deviations were subsequently calculated.
Western blotting. A nuclear extraction kit (Chemicon International, Temecula, CA, USA) was used to isolate cytoplasmic proteins. Proteins, 50 µg, from various groups were boiled for 5 min in sample buffer and were subsequently Cell proliferation and cell apoptosis assays. Cell proliferation assays were performed with cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan). SiHa and HeLa cells treated with nonsense sequence (SCR) or lentiviruses expressing iNOS-targeted shRNA (iNOS-SH) were seeded into 96-well plates at 5x10 3 per well in a 100 µl cell culture medium and maintained at 37˚C in a humidified incubator containing 5% CO 2 for 24 h. One hundred microlitres of 2% FBS medium was used as a control. After 96 cultures, 10 µl CCK-8 solution was added to the triplicate wells and incubated for 3 h. Subsequently, the absorbance at 450 nm was measured in order to calculate the number of vital cells in each well. Cell proliferation is represented as the mean percentage ± standard deviation of absorbance. Cell apoptosis assays were performed by flow cytometry with propidium iodide (PI) and Annexin V-fluorescein isothiocyanate (FITC) once the cells had been digested with trypsin, washed and harvested.
Short hairpin RNA (shRNA) interference, lentivirus production and infection. iNOS-SH shRNA was generated from two different annealed oligonucleotides (target 1: 5'-CCGGCCAGAAGCAGAATGTGACATCTC GAGTGGTCACATTCTGCTTCTGGTTTTTG-3' and 5'-AATTCAAAAACCAGAAGCAGAATGTGACATCTCGA
GAT G GT CACAT T C T G C T T C T G G -3'; t a r g e t 2: 5'-CCGGGAAGCGGTAACAAAGGAGATACTCGAGTATC T C C T T T G T T A C C G C T T C T T T T T G -3 '
a n d 5'-AATTCAAAAAGAAGCGGTAACAAAGGAGATACTCGAG TATCTCCT T TGT TACCG CT TC-3'; a nd t a rget 3: 5'-CCGGCGAGGACTATTTCTTTCAGCTCTCGAGAGCT GA A AGA A ATAGTCCTCGT T T T TG-3' and 5'-A A TTCAAAAACGAGGACTATTTCTTTCAGCTCTCGAGAGCT GAAAGAAATAGTCCTCG-3') that were inserted into the AgeI and EcoRI sites of SCR vector purchased from Addgene; the human iNOS target sequence is underlined. The control shRNA was purchased from Addgene. All target sequences were designed and verified as specific for iNOS by Blast searching against the human genome. The resulting plasmids, iNOS-SH1, iNOS-SH2 and iNOS-SH3, were sequenceverified.
To obtain a recombinant lentivirus, HEK-293T cells were cotransfected with the package, envelope and iNOS-SH constructs. The virus-containing supernatant was harvested following 60 h cotransfection and concentrated by ultracentrifugation at 100,000 x g for 2 h with an Avanti J-30I (Beckman Coulter, Miami, FL, USA). For infection, the viral stock was supplemented with 8 µg/ml polybrene.
Tumorigenicity assays in nude mice. All studies involving animals were approved by the Ethics Committee of Obstetrics and Gynecology Hospital of Fudan University (Shanghai, China). Five-to six-week-old female athymic BALB/c nude mice were purchased from Sino-British Sippr/BK Lab Animal Ltd, Co. (Shanghai, China). iNOS-SH and SCR-infected HeLa cells (1x10 6 ) were suspended in 100 µl PBS and were subcutaneously injected into the posterior flank of 4-5 week-old female nude mice. Tumor size measurement was performed every three days over the course of 4 weeks and the tumor volume was estimated using the formula: Volume = length x width 2 x 0.5. The comparison of tumor volumes between the iNOS-SH and vehicle control groups was performed using paired t-tests.
Immunohistochemisty (IHC).
Tissues were fixed in 10% buffered formalin fixative at room temperature overnight. Samples were subsequently deparaffinized in xylene, rehydrated through graded ethanol, quenched for endogenous peroxidase activity in 0.3% hydrogen peroxide and processed for antigen retrieval by microwave heating in 10 mM citrate buffer (pH 6.0) using antibodies against iNOS, VEGF, and myeloperoxidase (MPO) (Dako, Carpinteria, CA, USA). Immunostaining was performed according to the manufacturer's instructions using the ChemMate Dako EnVision Detection kit, Peroxidase/DAB, Rabbit/Mouse (DakoCytomation, Glostrup, Denmark), which resulted in a brown precipitate at the antigen site.
Statistical analysis. All results are expressed as the mean ± standard error of the mean. Differences were analyzed by Student's t-test with SPSS 15.0 software, (SPSS, Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Inhibition of iNOS expression in SiHa and HeLa cells.
In order to determine the function of iNOS in the development of cervical cancer, a number of SiHa and HeLa cells were not infected or infected with lentiviruses expressing a 20 base fragment of human shRNA and control scramble, respectively. The efficacy of this fragment in inhibiting the expression of iNOS in these cell lines was determined by western blotting, and SH3 was selected as the iNOS shRNA of the three shRNAs for its high knockdown efficiency (Fig. 1A) . According to the results of western blotting and qPCR, the iNOS protein product from the SiHa and HeLa cells was significantly different between the experimental and control groups following iNOS stable knockdown (P<0.05). In cells expressing iNOS-shRNA, there was significant inhibition of iNOS expression (60% mRNA knockdown in SiHa cells, and 75% mRNA knockdown in HeLa cells; >70% protein knockdown efficacy in the two cell lines) (Fig. 1) .
Effect of inhibiting iNOS expression on tumor growth in vitro and in vivo.
To test the function of iNOS in cervical cancer growth, cell proliferation was investigated following iNOS knockdown. As expected, the number of SiHa and HeLa cells decreased markedly under iNOS-SH downregulation, compared with the blank and scramble groups ( Fig. 2A and  B) . However, data from flow cytometry revealed a statistically significant increase in the levels of SiHa and HeLa apoptosis ( Fig. 2C and D) . The experimental evidence reveals the critical role of iNOS in SiHa and HeLa growth in vitro. In contrast to their growth in vitro, when SiHa and HeLa cells were inoculated into the flanks of nude mice, the iNOS-SH HeLa cells growth rate in vivo was significantly slower compared with that of the control cells (Fig. 3A and B) . Tumors derived from iNOS-SH SiHa cells exhibited a growth rate similar to that of iNOS-SH HeLa tumors. HeLa tumors became palpable and measurable 10 days after cell inoculation compared with SiHa tumors, which could be measured 13 days following inoculation. Following 20 days of growth, the mean tumor size of HeLa tumors was half that of the control tumors. Inhibition of iNOS expression in HeLa tumors was confirmed by IHC analysis iNOS (Fig. 3C and D) and VEGF ( Fig. 3E and F) of tumors with or without iNOS knockdown. (Fig. 4A and B) . Furthermore, the concentration of VEGF in the same supernatant was markedly reduced in the iNOS-shRNA group, compared with the control group, as determined by western blotting (Fig. 4C and D) .
iNOS increases VEGF levels in SiHa and HeLa cell cultures.
To assess whether NO is a mediator for the reduction of VEGF in the supernatant and iNOS-SH treated cells, sodium nitroprusside (SN), an exogenous NO donor, was applied to stimulate cells. The mRNA level of iNOS and VEGF in cells incubated in media with or without SN (DMSO, 0.25, 0.5 and 1 mM) were assessed ( Fig. 5A and B) . In all groups, the VEGF mRNA level (Fig. 5B ) demonstrated a significant increase with treatment with a high concentration of SN (0.5 mM), The fact that SN increased the supernatant concentration of NO in iNOS-SH SiHa and HeLa cells reveals that SN induced NO production in an iNOS-independent way ( Fig. 5C and D) . Furthermore, in SiHa and HeLa cells the stable knockdown of iNOS-SH, the protein levels of VEGF and iNOS peaked at 0.5 mM SN treatment, but exhibited a smaller increase with 1 mM SN ( Fig. 5E and F) .
In conclusion, the data indicated that the knockdown of iNOS based on depressed lentivirus proliferation of SiHa and HeLa, may be mimicked by applying an extrogenous NO donor. Furthermore, iNOS is capable of regulating the proliferation of cervical cancer cells and the expression of VEGF by regulating the concentration of NO. 
Discussion
In recent years, the incidence rate of cervical cancer has increased markedly, with an increasing trend in young females. However, the mechanisms underlying the disease remain unknown.
Several factors have been implicated in tumor development. One of the most prominent cytokines is VEGF, which induces sprouting angiogenesis, increases blood vessel permeability and maintains tumor vessel integrity (15) . VEGF expression has been shown to be a survival factor for blood vessels in SiHa (14). iNOS and VEGF are important in tumor growth. The level of iNOS is correlated with that of VEGF. One of the most important mechanisms is that angiogenesis is induced by iNOS, which is capable of synthesizing more NO, regulating VEGF levels in tumors. NO is capable of inducing VEGF expression and mediating the angiogenic effects of VEGF (16) . Therefore it was hypothesized that the decline in growth and vessel perfusion of SiHa and HeLa tumor cells may correlate with decreased VEGF expression. Notably, analyses of VEGF expression and production in tumor cells and explants following RNAi of iNOS revealed a correlation between VEGF and NO levels. This, coupled with previously published data, suggests that NO produced from iNOS activity is important for the maintenance of tumor blood vessel tone and function and further highlights the different roles of NOS isotypes and their tissue/cell type of origin in vivo (17) .
NO production is induced by numerous angiogenic stimuli and is an important extracellular and intracellular signaling molecule synthesized from arginine by NOS. Of the three NOS isoforms, including iNOS, endothelial (eNOS) and neuronal NOS, iNOS specifically produces the greatest quantities of NO and is associated with a number of pathologies (18) . Although their precise roles remain unclear, the activites of iNOS and eNOS have been implicated in tumor progression and angiogenesis, and their effectiveness appears to be dependent on their activity and distribution, the concentration and duration of exposure to NO and the intrinsic sensitivity of cells to NO (19) . The effect of altered NO levels on tumor growth and angiogenesis has also been exploited through pharmacological manipulation with either NO donors or NOS inhibitors.
In the present study, it was observed that iNOS knockdown results in the decreased proliferation of SiHa and HeLa cells and the concentration of VEGF in the supernatant, which means that iNOS regulates the growth of cervical cancer cells in a VEGF-dependent process. Further studies are required in order to confirm that SN is capable of rescuing the iNOS-induced decrease.
In conclusion, it was demonstrated i) Using a lentivirus-delivered RNAi approach that iNOS is a key modulator of tumor growth and angiogenesis; ii) that the level of VEGF correlates with the expression of iNOS in SiHa and HeLa cells, which may be mediated by the level of NO; and iii) that the level of NO generated in the tumor is lower than the concentration at which apoptosis occurs, which promotes growth and angiogenesis.
